Baiyunshan announced that Guangzhou Baiyunshan Mingxing Pharmaceutical Co., Ltd., a wholly-owned subsidiary of the company, received the “Drug Supplement Application Approval Notice” issued by the State Drug Administration. Norepinephrine bitartrate passed the consistent evaluation of generic drug quality and efficacy, and agreed to change prescriptions, production processes, registration standards, packaging materials and containers for direct contact with drugs, and revised instructions. This drug is used for blood pressure control in acute hypotensive states. Mingxing Pharmaceutical has invested about 1,255,700 yuan in research and development expenses for the drug's consistency evaluation. This review is conducive to improving the competitiveness of the drug market, and there is a risk of uncertainty in drug sales.

Baiyunshan announced that Guangzhou Baiyunshan Mingxing Pharmaceutical Co., Ltd., a wholly-owned subsidiary of the company, received the “Drug Supplement Application Approval Notice” issued by the State Drug Administration. Norepinephrine bitartrate passed the consistent evaluation of generic drug quality and efficacy, and agreed to change prescriptions, production processes, registration standards, packaging materials and containers for direct contact with drugs, and revised instructions. This drug is used for blood pressure control in acute hypotensive states. Mingxing Pharmaceutical has invested about 1,255,700 yuan in research and development expenses for the drug's consistency evaluation. This review is conducive to improving the competitiveness of the drug market, and there is a risk of uncertainty in drug sales.